Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Deloitte
Moodys
Colorcon
Boehringer Ingelheim
Cantor Fitzgerald
Chinese Patent Office
US Army
Accenture

Generated: June 23, 2018

DrugPatentWatch Database Preview

HUMALOG PEN Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Humalog Pen patents expire, and what generic alternatives are available?

Humalog Pen is a drug marketed by Lilly and is included in one NDA.

The generic ingredient in HUMALOG PEN is insulin lispro recombinant. There are thirty-nine drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the insulin lispro recombinant profile page.
Summary for HUMALOG PEN
US Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: 4
Clinical Trials: 111
DailyMed Link:HUMALOG PEN at DailyMed
Drug patent expirations by year for HUMALOG PEN
Pharmacology for HUMALOG PEN
Ingredient-typeInsulin
Drug ClassInsulin Analog
Medical Subject Heading (MeSH) Categories for HUMALOG PEN

US Patents and Regulatory Information for HUMALOG PEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly HUMALOG PEN insulin lispro recombinant INJECTABLE;INJECTION 020563-002 Aug 6, 1998 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for HUMALOG PEN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly HUMALOG PEN insulin lispro recombinant INJECTABLE;INJECTION 020563-002 Aug 6, 1998 ➤ Sign Up ➤ Sign Up
Lilly HUMALOG PEN insulin lispro recombinant INJECTABLE;INJECTION 020563-002 Aug 6, 1998 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
US Department of Justice
Cerilliant
Teva
Deloitte
Johnson and Johnson
Federal Trade Commission
Accenture
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.